Key players in market are focused on receiving approvals from the regulatory bodies for drugs used to treat ANCA vasculitis, which is expected to drive the market growth over the forecast period. For instance, in October 2021, ChemoCentryx, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved tavneos (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main forms of ANCA vasculitis), in combination with standard therapy.
Key Players
Major players operating in the global ANCA vasculitis drug market include ChemoCentryx, Inc., Vifor Pharma, GlaxoSmithKline plc, Amgen, Genentech, Inc., Pfizer Inc., Biogen, InflaRx GmbH, and AstraZeneca.
Anca Vasculitis Drug Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients